Toronto, Ontario – May 31, 2013 – Biologix Hair Inc. is pleased to report the Company's clinician licensing results for the period commencing March 1 through April 30, 2013.
During the two-month period, Biologix Hair's worldwide Clinician Licensing Department, headquartered in Toronto, Canada, has contracted on behalf of Biologix with 80 new medical services clinics located in 32 countries of which 27 are new countries Biologix previously had not penetrated.
Based on information provided by the new contracting clinics, the total number of existing patients represented by these 80 clinics is 2,038,500, of which an estimated 807,400 would be interested in either the hair loss prevention or hair loss regeneration treatment and are candidates for the Biologix Hair Therapy System™.
The updated Clinician Licensing totals from inception through the end of April 2013 show:
- Number of countries in which clinicians have been contracted:?
Increased from 11 to 38
- Licensed medical clinics that have signed contractual reservations to become certified Biologix Hair Therapy Centers™:
Increased from 196 to 276
- Total number of patients treated over the last 5 years by clinic network: ?
Increased 264% from 1,245,565 to 3,284,065
- Estimated number of existing patients who would be interested in either the hair loss prevention or hair loss regeneration treatment and are candidates for the Biologix Hair Therapy System™:?
Increased 259% from 508,526 to 1,315,926
Donna Lieder, Biologix Vice President of Clinician Licensing, stated, "During the recent period we witnessed tremendous increase in interest by the global medical community seeking to become certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
“We will continue to attend and exhibit at major medical symposiums around the world over the coming months where our technical clinician team can effectively network with leading medical practitioners. The recent conference in Monaco proved to be the trigger that spawned a global awakening as to the potential our patent-pending hair loss solution can provide when anticipated FDA and other regulatory approvals are secured.”
Note: Patient Data and Estimates Supplied by Licensed Clinicians. Last updated Apr 30, 2013.
GLOBAL CLINIC BREAKDOWN
A country-by-country breakdown of all 276 clinics contracted as of April 30, 2013 is as follows:
Here is what a few contracted clinicians had to say about why they decided to contract to join the certified Biologix Hair Therapy Center™ team:
Dr. Karen Kade, Dermatologist in Miami, Florida said: "If patients really thought there was good treatment for hair loss, they would besiege me with requests. We know 35-45% of adults suffer from androgenic alopecia; this does not count alopecia areata patients. There is a huge untapped market out there."
Dr. Joshua Berkowitz, Founder and Clinical Director of Wimpole Aesthetics, London said: “I first met the company in Monte Carlo and was amazed and impressed at the amount of care and research that had been done to get the Biologix Hair product to the marketplace … I am very excited at the prospect of being able to offer my patients a predictable, reliable and safe product for their hair loss problems. I am equally excited at the enhanced revenues and reputation this will bring to my medical clinic.”
Dr. Daniel McGrath of McGrath Medical in Austin, Texas said: "The reason I have chosen to be a future provider for Biologix Hair is because I have seen the results of the thousands of patients treated and I believe the future of hair loss treatment will be in the arena of scalp injectables. Patients want an effective minimally invasive option to treat their hair loss issues and Biologix Hair has that option for my patients."
About Biologix Hair Inc. and Biologix Hair Science Ltd.™
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd.™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment – the Biologix Hair Therapy System™ – and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and late 2011, more than 30,000 pre-clinical-trial treatments of Biologix Revive – the essence of the Biologix Hair Therapy System™ – were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. Among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT), with oversight and participation in this process by Nova Southeastern University. The R&D program is a necessary final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which nearly 150 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™ and is rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure purchasing and treatment rights for the Biologix Hair Therapy System™ if and when it is made available.
Although the Biologix Hair Therapy System™ is currently not able to be offered in more heavily regulated markets, such as the United States, Canada and the European Union, there are numerous countries and regions with less restrictive regulatory barriers that enable Biologix to initiate the availability of treatment via its rapidly expanding international network of certified clinicians in the near term while simultaneously focusing on obtaining regulatory approvals for all markets, worldwide.
Management is currently working together with its Medical Advisory Board and its team of legal advisors to determine in which strategic locations around the world to begin to allow commercial treatment options to be offered upon completion of the formula standardization process. Additionally, BHS is in the process of evaluating where best to open prototype fee-for-service hair therapy treatment centers that can also provide clinician training and may serve as clinical trial centers.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.